Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Mortality outcomes similar between vancomycin, beta-lactam for BSI

12 Sep 2019

The 30-day all-cause mortality is similar between definitive therapy with vancomycin or a beta-lactam among patients with an ampicillin-susceptible enterococcal bloodstream infection (BSI), a recent study has shown.

Definitive therapy was given to 186 patients with an ampicillin-susceptible enterococcal BSI, of which 45 (24.2 percent) received vancomycin and 141 (75.8 percent) beta-lactam.

No between-group difference was seen in the primary outcome of 30-day all-cause mortality (6.7 percent vs 7.1 percent; p=0.992). However, the vancomycin group had significantly higher all-cause mortality in a posthoc analysis 1 year after the index BSI (51 percent vs 33 percent; p=0.032).

In addition, definitive therapy with vancomycin had been shown to increase the risk of all-cause mortality at 1 year (hazard ratio [HR], 2.39, 95 percent CI, 1.41–4.04) in a Cox proportional hazards regression model.

“Whether definitive vancomycin is associated with poor long-term outcomes warrants further exploration,” the authors said.

This retrospective cohort study sought to determine whether definitive antibiotic selection affected outcomes for patients with an ampicillin-susceptible enterococcal BSI.

The authors included patients aged >18 years receiving definitive therapy with vancomycin or a beta-lactam for one or more blood cultures positive for Enterococcus spp. isolates between 2007 and 2014. A Kaplan-Meier curve with log-rank test was used to examine survival differences.

“De-escalation to a beta-lactam improves outcomes for patients with a methicillin-susceptible Staphylococcus aureus BSI,” the authors said. “Whether a similar strategy is appropriate for enterococcal species is less clear.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.